OP-EHEA191011_online 2313..2340 Page 1 Low-density lipoproteins cause atherosclerotic
cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus …

Anti-cancer peptides (ACPs) are a series of short peptides composed of 10–60 amino acids
that can inhibit tumour cell proliferation or migration, or suppress the formation of tumour …

Background Several commercial and academic autologous chimeric antigen receptor T-cell
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …

Chimeric antigen receptor (CAR) T cells are a novel class of anti-cancer therapy in which
autologous or allogeneic T cells are engineered to express a CAR targeting a membrane …

Chimeric antigen receptor (CAR) T-cell therapy is one of the most promising emerging
treatments for B-cell malignancies. Recently, two CAR T-cell products (axicabtagene …

Chimeric antigen receptor (CAR) T‐cell therapy is a promising immunotherapeutic treatment
concept that is changing the treatment approach to hematologic malignancies. The …

Hematological toxicity represents the most common grade≥ 3 toxicity after chimeric antigen
receptor (CAR) T-cell therapy. However, its underlying pathophysiology is incompletely …

Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR T) therapy
shows remarkable efficacy in patients with relapsed and/or refractory (R/R) multiple …

For hematopoietic cell transplantation (HCT) and cellular therapy (CT), clinical patient care
is localized, and practices may differ between countries and from center to center even …

The available treatments for relapsed or refractory (R/R) diffuse large B-cell lymphoma
(DLBCL) have experienced a dramatic change since 2017. Incremental advances in basic …